Inhibition of melanoma development in the Nras(Q61K):: Ink4a-/ mouse model by the small molecule BI-69A11

Pigment Cell and Melanoma Research

Volumn 26, Issue 1, 2013, Pages 136-142

  Feng, Yongmei ^a   Lau, Eric ^a   Scortegagna, Marzia ^a   Ruller, Chelsea ^a   De, Surya K ^a   Barile, Elisa ^a   Krajewski, Stan ^a   Aza Blanc, Pedro ^a   Williams, Roy ^a   Pinkerton, Anthony B ^a   Jackson, Michael ^a   Chin, Lynda ^b   Pellecchia, Maurizio ^a   Bosenberg, Marcus ^c   Ronai, Ze'ev A ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

BI 69A11; Melanoma model; Nras melanoma; Nras Ink4a; Small molecule inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BI 69A11; CD3 ANTIGEN; CD45 ANTIGEN; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INFILTRATION; CYTOSKELETON; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE MUTATION; HISTIOCYTIC SARCOMA; HUMAN; IMMUNOCOMPETENT CELL; INK4A GENE; MELANOMA; MOUSE; NONHUMAN; ONCOGENE N RAS; TUMOR MODEL; UPREGULATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD45; BENZIMIDAZOLES; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, INTRAPERITONEAL; KI-67 ANTIGEN; MELANOMA; MICE; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS B-RAF; QUINOLONES; RAS PROTEINS; SKIN NEOPLASMS; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84871404853     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12033     Document Type: Article

References (28)

1. Albino, A.P., Le Strange, R., Oliff, A.I., Furth, M.E., and Old, L.J. (1984). Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 308, 69-72.
2. Bhatia, S., Tykodi, S.S., and Thompson, J.A. (2009). Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23, 488-496.
3. Bichat, F., Mouawad, R., Solis-Recendez, G., Khayat, D., and Bastian, G. (1997). Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res. 17, 3393-3401.
4. Boyle, G.M., Martyn, A.C., and Parsons, P.G. (2005). Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res. 18, 160-166.
5. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
6. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
7. Dutton-Regester, K., and Hayward, N.K. (2012). Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res. 25, 144-154.
8. Feng, Y., Barile, E., De, S.K. et al. (2011). Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-kappaB pathways. Pigment Cell Melanoma Res. 24, 703-713.
9. Flaherty, K.T. (2012). Targeting metastatic melanoma. Annu. Rev. Med. 63, 171-183.
10. Forino, M., Jung, D., Easton, J.B., Houghton, P.J., and Pellecchia, M. (2005). Virtual docking approaches to protein kinase B inhibition. J. Med. Chem. 48, 2278-2281.
11. Frosina, G. (2009). DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol. Cancer Res. 7, 989-999.
12. Gaitonde, S., De, S.K., Tcherpakov, M., Dewing, A., Yuan, H., Riel-Mehan, M., Krajewski, S., Robertson, G., Pellecchia, M., and Ronai, Z. (2009). BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res. 22, 187-195.
13. Harbour, J.W. (2012). The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 25, 171-181.
14. Hatton, D.H., Mitchell, D.L., Strickland, P.T., and Johnson, R.T. (1995). Enhanced photoproduct repair: its role in the DNA damage-resistance phenotype of human malignant melanoma cells. Cancer Res. 55, 181-189.
15. Kamijo, T., Bodner, S., Van De Kamp, E., Randle, D.H., and Sherr, C.J. (1999). Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217-2222.
16. Kang, W.K., Lee, I., and Park, C. (2005). Characterization of RhoA-mediated chemoresistance in gastric cancer cells. Cancer Res. Treat. 37, 251-256.
17. Linos, K., Slominski, A., Ross, J.S., and Carlson, J.A. (2011). Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. Biomark. Med. 5, 333-360.
18. Luo, Y., Li, X., Huang, X., Wong, Y.S., Chen, T., Zhang, Y., and Zheng, W. (2011). 1, 4-Diselenophene-1, 4-diketone triggers caspase-dependent apoptosis in human melanoma A375 cells through induction of mitochondrial dysfunction. Chem. Pharm. Bull. 59, 1227-1232.
19. Paraiso, K.H., Fedorenko, I.V., Cantini, L.P., Munko, A.C., Hall, M., Sondak, V.K., Messina, J.L., Flaherty, K.T., and Smalley, K.S. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730.
20. Paraiso, K.H., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
21. Redmond, K.M., Wilson, T.R., Johnston, P.G., and Longley, D.B. (2008). Resistance mechanisms to cancer chemotherapy. Front. Biosci. 13, 5138-5154.
22. Ribas, A., and Flaherty, K.T. (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426-433.
23. Santos, C.R., and Schulze, A. (2012). Lipid metabolism in cancer. FEBS J. 279, 2610-2623.
24. Shah, M., Bhoumik, A., Goel, V. et al. (2010). A role for ATF2 in regulating MITF and melanoma development. PLoS Genet. 6, e1001258.
25. Singh, S., Khan, A.R., and Gupta, A.K. (2012). Role of glutathione in cancer pathophysiology and therapeutic interventions. J. Exp. Ther. Oncol. 9, 303-316.
26. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
27. Walia, V., Mu, E.W., Lin, J.C., and Samuels, Y. (2012). Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res. 25, 155-170.
28. Woodman, S.E., Lazar, A.J., Aldape, K.D., and Davies, M.A. (2012). New strategies in melanoma: molecular testing in advanced disease. Clin. Cancer Res. 18, 1195-1200.